SUNMAX BIOTECHNOLOGY CO., LTD. Sunmax Biotechnology Co., Ltd. Share Price
Equities
4728
TW0004728001
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 334 TWD | -1.18% |
|
+6.71% | +63.73% |
| Sales 2022 | 1.4B 43.28M 3.41B | Sales 2023 | 1.69B 52.21M 4.11B | Capitalization | 11.11B 343M 27.06B |
|---|---|---|---|---|---|
| Net income 2022 | 534M 16.51M 1.3B | Net income 2023 | 626M 19.35M 1.52B | EV / Sales 2022 | 4.75 x |
| Net cash position 2022 | 754M 23.29M 1.84B | Net cash position 2023 | 793M 24.5M 1.93B | EV / Sales 2023 | 6.11 x |
| P/E ratio 2022 |
13.9
x | P/E ratio 2023 |
17.8
x | Employees | - |
| Yield 2022 |
6.99% | Yield 2023 |
5.39% | Free-Float | 52.94% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.18% | ||
| 1 week | +6.71% | ||
| Current month | +7.05% | ||
| 1 month | +38.02% | ||
| 3 months | +59.05% | ||
| 6 months | +65.76% | ||
| Current year | +63.73% |
1 week
316.00
341.50
1 month
242.00341.50
Current year
191.50341.50
1 year
175.00341.50
3 years
64.60341.50
5 years
51.00341.50
10 years
21.25341.50
| Managers | Title | Age | Since |
|---|---|---|---|
Chuan Yuan Lin
CEO | Chief Executive Officer | - | 13/05/14 |
Ya Fan Wang
DFI | Director of Finance/CFO | - | - |
Yu Te Lin
CTO | Chief Tech/Sci/R&D Officer | - | 10/09/02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kuo Chou Tsai
CHM | Chairman | - | - |
Shih Kuang Lue
BRD | Director/Board Member | - | 29/06/08 |
Kuo Chuan Chiang
BRD | Director/Board Member | - | 29/06/08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 346.5 | +3.74% | 279,091 |
| 19/06/24 | 334 | -1.18% | 223,589 |
| 18/06/24 | 338 | +4.32% | 154,400 |
| 17/06/24 | 324 | +2.05% | 76,873 |
| 14/06/24 | 317.5 | -2.61% | 115,558 |
End-of-day quote Taipei Exchange, June 18, 2024
More quotes
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.
Calendar
08/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +63.73% | 561M | |
| +35.59% | 51.07B | |
| -8.20% | 38.78B | |
| +35.03% | 38.61B | |
| -8.98% | 27.32B | |
| +11.63% | 26.35B | |
| -19.12% | 19.46B | |
| +40.45% | 13.58B | |
| +30.25% | 12.46B | |
| -4.11% | 11.75B |
- Stock Market
- Equities
- 4728 Stock
